Introduction

Tangier disease is a rare autosomal recessive disorder characterised by mutations in the ATP-binding cassette transporter A1 (ABCA1) gene. This gene is key in the removal of cholesterol from cells, which leads to defective removal of cholesterol and its accumulation in various tissues. This condition is primarily associated with significantly reduced high-density lipoprotein (HDL) cholesterol levels, often leading to hepatosplenomegaly and systemic lipid accumulation. Due to its profound impact on cholesterol metabolism, Tangier disease is a valuable model for understanding atherosclerosis, lipid transport mechanisms, and metabolic syndromes. Understanding the implications of Tangier disease on the liver and spleen is crucial for accurate diagnosis, prognosis, and potential therapeutic interventions.

Pathophysiology of tangier disease

The ABCA1 protein plays a vital role in facilitating the efflux of cholesterol and phospholipids from cells to lipid-poor apolipoprotein A-I (ApoA-I), which forms HDL particles. The loss-of-function mutation in ABCA1 impairs this process, resulting in:

• Lipid accumulation within macrophages and other reticuloendothelial cells
• Progressive hepatosplenomegaly, a hallmark of systemic cholesterol ester deposition- Neuropathy and cardiovascular complications due to altered lipid homeostasis

Mechanisms of lipid accumulation

In Tangier disease, the liver and spleen become significant sites of abnormal lipid storage. The accumulation of cholesterol esters in Kupffer cells (liver macrophages) and splenic macrophages leads to the enlargement and dysfunction of these organs. Chronic lipid overload can contribute to fibrosis, cirrhosis, and altered immune function, increasing susceptibility to systemic infections and metabolic disturbances. 

Hepatic manifestations of tangier disease

Hepatomegaly and liver dysfunction

Hepatomegaly is frequently found in Tangier disease due to excessive lipid accumulation in hepatic and Kupffer cells. While liver enzyme abnormalities are not always present, some individuals may exhibit elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, suggesting hepatic stress. Over time, chronic hepatic dysfunction may contribute to metabolic imbalances, including hyperlipidemia (high cholesterol and triglycerides) and insulin resistance, which further exacerbate disease progression.

Risk of non-alcoholic fatty liver disease (NAFLD)

The impaired cholesterol efflux mechanism in Tangier disease increases susceptibility to NAFLD, which can progress to:

• Non-alcoholic steatohepatitis (NASH), a severe inflammatory condition
• Hepatic fibrosis and cirrhosis, leading to progressive liver dysfunction
• Hepatocellular carcinoma (HCC), though rare, remains a concern in chronic hepatic lipid overload

Liver histopathology

Liver biopsies from Tangier patients often reveal foamy macrophages, hepatocyte ballooning, and perisinusoidal fibrosis, reflecting chronic lipid deposition. The presence of cholesterol-laden vacuoles within Kupffer cells is a distinguishing histological feature. Progressive liver damage can further impact hepatic detoxification and metabolic pathways, increasing systemic oxidative stress and inflammation.

Splenic manifestations of tangier disease

Splenomegaly and functional implications

The spleen, a primary organ of the mononuclear phagocyte system (MPS), exhibits excessive lipid accumulation in Tangier disease, leading to splenomegaly. Clinically, this can cause:

• Hypersplenism, resulting in anaemia, leukopenia, and thrombocytopenia
• Compromised immune response, increasing the risk of recurrent bacterial and viral infections
• Increased risk of haemorrhage due to impaired platelet function and excessive spleen enlargement

Histopathological findings in the spleen

Microscopic analysis of affected spleens shows lipid-laden macrophages, reduced lymphoid follicles, and structural disorganisation. These changes indicate chronic inflammatory activation and phagocytic dysfunction, impacting overall haematological balance. The disruption of standard splenic architecture can further impair immune surveillance and pathogen clearance, making patients more vulnerable to opportunistic infections.

Clinical presentation and diagnosis

Symptoms indicative of hepatosplenomegaly

• Abdominal discomfort and distension due to liver and spleen enlargement
• Fatigue and malaise due to metabolic dysfunction and systemic inflammation
• Yellow-orange tonsils, a pathognomonic feature of Tangier disease
• Peripheral neuropathy and muscle weakness, potentially affecting mobility
• Increased susceptibility to infections, especially respiratory and gastrointestinal infections

Diagnostic approaches

• Lipid Profile: Very low HDL cholesterol levels (<5 mg/dL), with elevated triglycerides
• Genetic Testing: Identification of ABCA1 mutations via next-generation sequencing (NGS)
• Imaging Studies: Ultrasound, CT, or MRI to evaluate organ enlargement and lipid deposition
• Liver and Spleen Biopsy: Confirmation of lipid-laden cells and fibrosis progression

Treatment and management strategies

There is no definitive cure for Tangier disease, but therapeutic interventions focus on symptom management, reducing complications, and improving quality of life.

Lifestyle and dietary modifications

• A low-fat, high-fibre diet to minimise cholesterol accumulation and support liver function
• Regular physical activity improves metabolic function and cardiovascular health
• Avoidance of alcohol and hepatotoxic substances, reducing hepatic stress

Pharmacological interventions

• Statins and fibrates: Limited efficacy due to low HDL levels, but may help manage triglycerides
• Liver-supportive therapies: Antioxidants, hepatoprotective agents (e.g., N-acetylcysteine)
• Experimental approaches: Gene therapy targeting ABCA1 function and HDL metabolism

Haematological and immunological support

• Splenectomy in severe cases of hypersplenism and haematological complications
• Regular monitoring of blood counts and immune function, and preventing infections

Future directions in research

Ongoing research aims to explore:

• Gene editing techniques (CRISPR-Cas9) to correct ABCA1 mutations and restore cholesterol efflux
• Targeted HDL-mimetic therapies to improve cholesterol transport and reduce lipid deposition
• Liver-directed regenerative medicine approaches, including stem cell therapy
• Development of pharmacological chaperones, stabilising ABCA1 protein function

FAQs

What causes hepatosplenomegaly in Tangier disease?

Hepatosplenomegaly in Tangier disease is caused by the accumulation of cholesterol esters in Kupffer cells (liver) and splenic macrophages, leading to organ enlargement and dysfunction.

Is Tangier disease life-threatening?

Tangier disease is not typically fatal, but it significantly increases the risk of cardiovascular disease, metabolic disorders, and immune dysfunction, requiring lifelong management.

Can Tangier disease be cured?

There is no cure for Tangier disease, but lifestyle modifications, symptom management, and potential gene therapy are active research areas.

How is tangier disease diagnosed?

It is diagnosed through lipid profiling, genetic testing (ABCA1 mutations), imaging studies (hepatosplenomegaly), and biopsy analysis.

Why do patients with tangier disease have yellow-orange tonsils?

The deposition of cholesterol-laden macrophages in the tonsils leads to their characteristic yellow-orange discolouration, a hallmark of Tangier disease.

Summary

Tangier disease, a rare genetic disorder caused by ABCA1 mutations, which leads to hepatosplenomegaly (enlarged liver and spleen) and systemic lipid accumulation. The liver and spleen are significantly affected, resulting in metabolic disturbances, immune dysfunction, and increased cardiovascular risks. While current treatments focus on managing symptoms, emerging research on gene therapy, HDL-modulating agents, and metabolic interventions holds promise for the future.